December 7, 2015
Japanese pharmaceutical company Takeda says it is renewing its partnership with the Structural Genomics Consortium (SGC) to further fund collective drug research aimed at bringing new, more effective medicines to patients faster. Takeda is investing $7.5 million into the SGC, adding to its initial investment in 2012 of $5 million. The SGC is a unique, open-source collaboration of more than 200 scientists from academia and industry working on pre-competitive, human biology and early-stage drug research, the results of which are available openly to the whole scientific community. The SGC is based at the University of Toronto, operating from the MaRS Discovery District in downtown Toronto, and at the Universities of Campinas (Brazil), North Carolina (Chapel Hill, USA) and Oxford (UK). Takeda is the leading pharmaceutical company in Japan and among the top 15 in the world.
Click here for full article.